Editorial: response to tofacitinib is associated with high rates of long-term treatment persistence
Aliment Pharmacol Ther
.
2022 May;55(9):1222-1223.
doi: 10.1111/apt.16891.
Authors
Wenfei Wang
1
,
Joel Pekow
1
Affiliation
1
IBD Center, University of Chicago Medicine, Chicago, Illinois, USA.
PMID:
35429025
DOI:
10.1111/apt.16891
No abstract available
Publication types
Editorial
Comment
MeSH terms
Antirheumatic Agents* / therapeutic use
Arthritis, Rheumatoid* / drug therapy
Humans
Piperidines / adverse effects
Pyrimidines / adverse effects
Substances
tofacitinib
Antirheumatic Agents
Piperidines
Pyrimidines